Clinical trial
Trial of Ondansetron as a Parkinson's HAllucinations Treatment
NCT04167813 · University College, London, Other · Active, not recruiting
Key facts
| NCT number | NCT04167813 |
|---|---|
| Title | Trial of Ondansetron as a Parkinson's HAllucinations Treatment |
| Official title | Trial of Ondansetron as a Parkinson's HAllucinations Treatment |
| Acronym | TOP HAT |
| Lead sponsor | University College, London, Other |
| Collaborators | MODEPHARMA Limited Parkinson's UK PRIMENT SEALED ENVELOPE Wasdell Packaging Ltd Custom Pharmaceuticals Limited |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Hallucinations, Dementia With Lewy Bodies |
| Intervention type | Drug |
| Interventions | Ondansetron 8mg or matched placebo tablets |
| Enrollment | 168 |
| Start date | Oct 1, 2021 |
| Primary completion | Aug 30, 2024 |
| Completion | Aug 30, 2024 |
| First posted | Nov 19, 2019 |
| Last update posted | Mar 27, 2024 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: